Lv1
8 积分 2024-02-10 加入
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1天前
待确认
An Alternative Non-Invasive Screening Model for Liver Fibrosis among US Adults at Risk of MASLD
2天前
已完结
The steatosis‐associated fibrosis estimator (SAFE) score: A tool to detect low‐risk NAFLD in primary care
2天前
已完结
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
15天前
已完结
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease
15天前
已完结
Implementation of a liver health check in people with type 2 diabetes
15天前
已完结
MASLD: a disease in flux
15天前
已完结
Steatotic liver disease
15天前
已完结
Predicting Liver-Related Outcomes in Steatotic Liver Disease
15天前
已完结
Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
20天前
已完结
皖公网安备34019202002308
